EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON INFECTIONS IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING DARATUMUMAB

Anti-CD38 monoclonal antibodies have led to improved response rates, progression-free and overall survival in randomized clinical trials (RCTs) of multiple myeloma (MM) patients. However, CD38 is expressed on both malignant and normal plasma cells, so anti-CD38 therapy can lead to hypogammaglobulinemia (HGG). Already present at baseline in many MM patients, HGG can increase the risk of infections. In RCTs, daratumumab containing arms have been associated with an increased risk of infections, particularly in the respiratory tract. To date, there have been no studies on interventions to reduce this risk. In this retrospective case-crossover study of patients receiving daratumumab, we compared the rates of infection while on and off intravenous immunoglobulin (IVIG) replacement therapy.